Navigation Links
New Ray of Hope for HIV Patients
Date:11/9/2012

BANGALORE, November 9, 2012 /PRNewswire/ --

DNA Gene Therapy for Degenerative Diseases

In today's reality, terms like genetic engineering and gene therapy have become facts which prophets of science had only dreamt about few years ago. Pain, disability and disease have long plagued mankind, medicine has long sought its answers, research and development are yet uncovering labyrinths of technology to reach to a panacea.

Dr.Agarwal Hospitals nestled in bubbling Bangalore has brought out a customized version of GENE THERAPY where the patient's own peripheral capillary blood (one drop) is taken as the raw stock admixed with Mana (DNA activator) it brings back healthy or fetal DNA of the same patient. This is then used as injections to the same patient within seconds of the mixture. A course of ten injections is given over a span of one week to ten days bringing about a healthy change in the patients course of disease.

Over 20 years of research conducted by Dr.Agarwal Hospitals on genetic engineering, where last 8 years have been spent on treating over 12000 patients through variety of illness in different stages of disease has brought new hope to mankind.

Mana (DNA activator) a propriety formula is taken in a syringe and customized with a drop of the patient's blood. This forms the patients healthy DNA in vitro and is given back to the patient as sub cutaneous injections over a period of ten days every month for severe conditions.

Mana is a DNA activator - proven to recreate patients own healthy DNA  

When Mana & Plasma are mixed within the first second healthy DNA strands start amplifying (proven through research and validation)

It's the patient's own DNA being given back : No Side Effects

Dr.Sunita Rana Agarwal, Chief Scientist, Dr Agarwal Hospitals & Gene Research Foundation, carried out the research in this field on patients who were HIV positive. The CD4 ratio counts varied from 186 to 358 from 2004. In 90% of the patients CD4 ratio has increased to above 500 cells per micro liter.

The customization of the patient's blood with the DNA activator leads to amplification of the DNA and also gives a younger and healthier look when seen under the microscope.

DNA Gene Therapy, administered at Gene Research Foundation, genetically modifies the cell which becomes resistant to the virus. The patients have an increased immunity thereby giving them stability and no symptoms typical of HIV.

All the patients who were in the study group were not on anti retroviral treatment.

The injections of this genetically modified DNA Gene Therapy are safe and well tolerated by patients with no side effects.

The aim of Dr Agarwal Hospitals & Gene Research Foundation is to make this treatment more efficient, effective and affordable.

Gene Research Foundation is further researching to find a permanent cure for HIV.

For further information, please contact Dr Agarwal Hospitals & Gene Research foundation.

Dr Agarwal Hospitals & Gene Research Foundation

15 Eagle Street

Langford Town

Bangalore 560 025

Karnataka, India

Contact Person: Pankaj Sondhi

Email: generesearchfoundation@gmail.com

Mobile: +91-9845010510

India Phone (91)80 22223100, 22240200, 22240736, 22221242 Fax (91)80 22221941 www.managene.orgwww.dragarwal.in


'/>"/>
SOURCE Dr.Agarwal Hospitals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. DioGenix MSPrecise Identifies Early-Stage Patients with Multiple Sclerosis
2. Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer
3. Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients
4. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
5. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
6. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
7. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
8. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
9. New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients
10. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
11. Prioritizing lab testing for patients on antiretroviral treatment in resource-constrained settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):